MK-9 Nanoparticle Formulation for Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of vitamin K2, particularly MK-9, suffer from poor solubility and stability issues, limiting their effectiveness in treating conditions such as vascular calcification and bone diseases in patients with chronic kidney disease (CKD), and there is a need for improved delivery methods to enhance bioavailability.
Innovation Solution
Development of nano-sized particles of vitamin K2, specifically MK-9, with controlled particle sizes ranging from 0.1 nm to 1,000 nm, stabilized by emulsifiers and bioavailability enhancers, which are prepared using homogenization techniques to increase solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations of vitamin K2 (MK-9) are used, then the basic nutritional requirement is met, but solubility and stability issues limit effectiveness in treating vascular calcification and bone diseases
Solution Approach 1:
The patent divides the vitamin K2 molecule into nano-sized particles (0.1 nm to 1,000 nm) to improve solubility and stability. This segmentation at the nanoscale allows the vitamin to be more effectively absorbed and utilized by the body, resolving the contradiction between basic nutritional requirement and therapeutic effectiveness.
Solution Approach 2:
The patent changes the physical parameters of vitamin K2 by controlling particle size within the nano-range (0.1 nm to 1,000 nm) and adjusting surface properties through homogenization. This parameter change enhances solubility and stability, enabling the vitamin to effectively treat vascular calcification and bone diseases while maintaining basic nutritional function.
2Quantity of substance
If nano-sized particles are prepared using homogenization techniques, then solubility increases up to 20 times, but the complexity of preparation and stabilization processes increases
Solution Approach 1:
The patent introduces emulsifiers and bioavailability enhancers as intermediary substances to facilitate the homogenization process. These intermediaries enable the formation of stable nano-sized particles with enhanced solubility (up to 20 times) while managing the complexity of the preparation process through chemical assistance.
Solution Approach 2:
The patent applies homogenization techniques to change the physical state of vitamin K2 from conventional form to nano-sized particles. This parameter change achieves up to 20 times increased solubility while the process complexity is managed through standardized homogenization protocols and stabilization formulations.
3Reliability
If nano-sized vitamin K2 particles are administered, then serum levels increase and treatment outcomes improve, but the difficulty of detecting and measuring particle size and distribution increases
Solution Approach 1:
The patent incorporates monitoring and measurement of particle size and distribution as feedback mechanisms in the formulation process. By continuously measuring these parameters and adjusting the homogenization and stabilization processes accordingly, the patent ensures consistent nano-sized particle formation (0.1 nm to 1,000 nm) that reliably increases serum levels and improves treatment outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano-sized vitamin K2 particles demonstrate enhanced solubility, up to 20 times greater than non-homogenized forms, effectively increasing serum levels and improving treatment outcomes for conditions like vascular calcification, bone diseases, and other vitamin K-associated disorders.
Implementation Method 1
prepared using homogenization techniques to increase solubility and bioavailability
Implementation Method 2
stabilized by emulsifiers and bioavailability enhancers
Data Source
AI summary
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.